CLINICAL TRIALS PROFILE FOR SECRETIN SYNTHETIC PORCINE

All Clinical Trials for SECRETIN SYNTHETIC PORCINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00065962 ↗	Secretin for the Treatment of Autism	Completed	National Institute on Deafness and Other Communication Disorders (NIDCD)	Phase 3	1999-06-01	Many drugs used to treat autism target specific symptoms, such as hyperactivity and aggressiveness. Few drugs target the core autistic symptoms of impaired social interaction and communication. This study will evaluate two forms of the drug secretin for the treatment of core autistic symptoms.
NCT00065962 ↗	Secretin for the Treatment of Autism	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 3	1999-06-01	Many drugs used to treat autism target specific symptoms, such as hyperactivity and aggressiveness. Few drugs target the core autistic symptoms of impaired social interaction and communication. This study will evaluate two forms of the drug secretin for the treatment of core autistic symptoms.
NCT00620919 ↗	Secretin Enhanced Multidetector CT Pancreatography for Evaluation of Known or Suspected Chronic Pancreatitis	Terminated	Massachusetts General Hospital	Phase 1	2008-02-01	1. To assess the effect of RG1068 at a dose of 0.2 mcg/kg intravenously (IV) on the diameter of the pancreatic duct when used during Multidetector Computed Tomography (MDCT) of the pancreas. 2. To demonstrate that RG1068-enhanced MDCT improves image quality of the pancreas in patients with chronic pancreatitis. 3. To evaluate if RG1068 enhanced MDCT results in improved delineation of structural abnormalities of the pancreatic duct as compared to non-enhanced MDCT.
NCT00621283 ↗	Secretin Enhanced MRCP for Evaluation of Pancreatic Duct in Pediatric Population	Terminated	Massachusetts General Hospital	Phase 1	2008-02-01	1. To assess the effect of RG1068 at a dose of 0.2 mcg/kg intravenously (IV) on the diameter of the pancreatic duct when used during Magnetic Resonance Pancreatography. 2. To demonstrate that RG1068-enhanced MRCP improves image quality relative to unenhanced MRCP in patients with unexplained acute recurrent pancreatitis (ARP) and chronic pancreatitis. 3. To evaluate if the use of RG1068-enhanced MRCP improves structural delineation of the pancreatic duct as compared to the non-enhanced MRCP. 4. To assess pancreatic exocrine function by quantifying pancreatic fluid output into the duodenum and the apparent diffusion coefficient of the pancreas.
NCT00621556 ↗	Secretin Enhanced MRCP for Evaluation of the Known or Suspected Intraductal Papillary Mucinous Neoplasms of the Pancreas	Terminated	Massachusetts General Hospital	Phase 1	2008-02-01	1. To assess the effect of RG1068 at a dose of 0.2 mcg/kg intravenously (IV) on the diameter of the pancreatic duct when used during Magnetic Resonance Pancreatography 2. To demonstrate that RG1068-enhanced MRCP improves detection and characterization of intraductal papillary mucinous neoplasms (IPMN) relative to unenhanced MRCP in patients with suspected IPMN 3. To correlate findings on MRCP with histologically confirmed malignancy

Clinical Trial Conditions for SECRETIN SYNTHETIC PORCINE

Condition Name

Condition Name for SECRETIN SYNTHETIC PORCINE
Intervention	Trials
Chronic Pancreatitis	2
Acute Recurrent Pancreatitis	1
Autism	1
Intraductal Papillary Mucinous Neoplasms	1

Condition MeSH

Condition MeSH for SECRETIN SYNTHETIC PORCINE
Intervention	Trials
Pancreatitis, Chronic	2
Pancreatitis	2
Autistic Disorder	1
Pancreatic Neoplasms	1

Clinical Trial Locations for SECRETIN SYNTHETIC PORCINE

Trials by Country

Trials by Country for SECRETIN SYNTHETIC PORCINE
Location	Trials
United States	5

Trials by US State

Trials by US State for SECRETIN SYNTHETIC PORCINE
Location	Trials
Massachusetts	3
Washington	1
Colorado	1

Clinical Trial Progress for SECRETIN SYNTHETIC PORCINE

Clinical Trial Phase

Clinical Trial Phase for SECRETIN SYNTHETIC PORCINE
Clinical Trial Phase	Trials
Phase 3	1
Phase 1	3

Clinical Trial Status

Clinical Trial Status for SECRETIN SYNTHETIC PORCINE
Clinical Trial Phase	Trials
Terminated	3
Completed	1

Clinical Trial Sponsors for SECRETIN SYNTHETIC PORCINE

Sponsor Name

Sponsor Name for SECRETIN SYNTHETIC PORCINE
Sponsor	Trials
Massachusetts General Hospital	3
National Institute on Deafness and Other Communication Disorders (NIDCD)	1
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	1

Sponsor Type

Sponsor Type for SECRETIN SYNTHETIC PORCINE
Sponsor	Trials
Other	3
NIH	2

SECRETIN SYNTHETIC PORCINE Market Analysis and Financial Projection

Secretin Synthetic Porcine: Clinical Trials, Market Analysis, and Projections

Introduction to Secretin Synthetic Porcine

Secretin, a hormone produced by the duodenum, plays a crucial role in the diagnosis and management of various gastrointestinal disorders. Synthetic porcine secretin has emerged as a significant alternative to biologically-derived porcine secretin, especially given the latter's unavailability in some regions. Here, we delve into the clinical trials, market analysis, and future projections for synthetic porcine secretin.

Clinical Trials and Efficacy

Diagnosis of Gastrointestinal Disorders

Synthetic porcine secretin is primarily used for the diagnosis of conditions such as Zollinger-Ellison Syndrome (ZES) and exocrine pancreas dysfunction. Clinical trials have shown that synthetic porcine secretin is as effective as biologically-derived porcine secretin in these diagnoses.

In a randomized controlled crossover study, synthetic porcine secretin was compared to biologically-derived porcine secretin and synthetic human secretin in patients with ZES. The results indicated complete agreement between all three agents using the FDA-approved criterion for positive secretin testing, with minimal differences in serum gastrin concentration increases[5].

Autism Trials

Although not the primary use, synthetic porcine secretin has been explored in other clinical contexts, such as autism. However, a randomized, double-blind, placebo-controlled trial found no evidence that either biologic or synthetic porcine secretin provided any amelioration of autism symptoms beyond the placebo effect[1].

Market Analysis

Global Market Overview

The global synthetic porcine secretin market is expected to grow significantly over the next few years. The market report for 2024 highlights key insights, including market size, revenue share, forecast, and CAGR. The base year for calculations is 2023, with historical data from 2019 to 2023 and forecasted data from 2025 to 2031[2].

Market Segments and Regional Analysis

The market is segmented based on type, application, and region. The segment accounting for the largest share of the global synthetic porcine secretin market is typically the diagnostic segment, given its primary use in diagnosing gastrointestinal disorders.

Regional analysis indicates that certain regions, such as North America and Europe, are expected to dominate the market due to advanced healthcare infrastructure and higher adoption rates of diagnostic technologies[2].

Market Drivers and Restraints

Key drivers of the synthetic porcine secretin market include the increasing need for accurate diagnosis of gastrointestinal disorders, the unavailability of biologically-derived porcine secretin in some regions, and advancements in diagnostic technologies.

However, the market also faces restraints such as potential hypersensitivity reactions to porcine products, regulatory hurdles, and competition from other diagnostic agents[2].

Market Projections

Growth Rate and Forecast

The synthetic porcine secretin market is projected to grow at a significant CAGR during the forecast period from 2025 to 2031. This growth is driven by increasing demand for diagnostic tools, especially in regions with high prevalence rates of gastrointestinal disorders.

Regional Dominance

North America and Europe are expected to continue their dominance in the market due to their well-established healthcare systems and high adoption rates of new diagnostic technologies. However, emerging markets in Asia-Pacific are also expected to show significant growth due to improving healthcare infrastructure and increasing awareness of gastrointestinal disorders[2].

Technological Trends and Future Outlook

Role of AI in Clinical Trials

The integration of artificial intelligence (AI) in clinical trials is expected to revolutionize the drug development process, including the development and testing of synthetic porcine secretin. AI can streamline data analysis, enhance patient recruitment, and predict future trial outcomes, making the entire process more efficient and cost-effective[3].

Personalized Medicine

The future of synthetic porcine secretin lies in its potential to be part of personalized medicine approaches. With AI-driven insights, synthetic porcine secretin could be tailored to individual patient needs, enhancing its diagnostic and therapeutic efficacy.

Safety and Adverse Reactions

Hypersensitivity Reactions

One of the significant concerns with synthetic porcine secretin is the potential for hypersensitivity reactions. Clinical trials and FDA labels emphasize the need for a test dose to monitor for acute hypersensitivity reactions before administering the full dose[4].

Adverse Reactions

Common adverse reactions reported in clinical trials include those related to the administration of the drug, such as injection site reactions and transient changes in serum gastrin levels. However, these reactions are generally mild and well-tolerated[4].

Key Takeaways

• Efficacy in Diagnostics: Synthetic porcine secretin is effective in diagnosing Zollinger-Ellison Syndrome and exocrine pancreas dysfunction.
• Market Growth: The global market for synthetic porcine secretin is expected to grow significantly, driven by increasing demand for diagnostic tools.
• Regional Dominance: North America and Europe are expected to dominate the market, with emerging markets in Asia-Pacific showing potential for growth.
• Technological Trends: AI integration in clinical trials will enhance the development and testing of synthetic porcine secretin.
• Safety Considerations: Hypersensitivity reactions are a significant concern and require careful monitoring.

FAQs

What is the primary use of synthetic porcine secretin?

Synthetic porcine secretin is primarily used for the diagnosis of gastrointestinal disorders such as Zollinger-Ellison Syndrome and exocrine pancreas dysfunction.

What are the key drivers of the synthetic porcine secretin market?

Key drivers include the increasing need for accurate diagnosis of gastrointestinal disorders, the unavailability of biologically-derived porcine secretin, and advancements in diagnostic technologies.

Which regions are expected to dominate the synthetic porcine secretin market?

North America and Europe are expected to dominate the market, with emerging markets in Asia-Pacific showing potential for growth.

What role does AI play in the development of synthetic porcine secretin?

AI can streamline data analysis, enhance patient recruitment, and predict future trial outcomes, making the entire process more efficient and cost-effective.

What are the common adverse reactions associated with synthetic porcine secretin?

Common adverse reactions include hypersensitivity reactions and transient changes in serum gastrin levels, which are generally mild and well-tolerated.

Sources

1. A randomized, double-blind, placebo-controlled trial of porcine secretin in autism. PubMed.
2. Global Synthetic Porcine Secretin Market Report 2024 Edition. Cognitive Market Research.
3. AI in Clinical Trials Market Size to Reach USD 20.16 Billion By 2033. BioSpace.
4. PORCINE SECRETIN for injection Label. FDA.
5. A randomized controlled crossover study comparing synthetic secretin products. PubMed.